Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Friday. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $1.04 on Friday. The company has a market capitalization of $56.87 million, a P/E ratio of -2.89 and a beta of 0.58. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.59. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The stock has a 50 day moving average price of $0.92 and a two-hundred day moving average price of $1.02.

Institutional Investors Weigh In On Cytosorbents

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares in the last quarter. Atomi Financial Group Inc. purchased a new position in shares of Cytosorbents during the 3rd quarter worth approximately $51,000. Finally, Sargent Investment Group LLC raised its position in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after acquiring an additional 67,181 shares in the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.